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he significant advancesmade in ultrasoundmicrobubble technology now permits reliable, reproducible
eft ventricular opacification, and this review reiterates the evidence that has shown contrast echocardi-
graphy to be clinically effective, to reduce downstream costs and to spare patients further, potentially
azardous investigations. Despite the evidence and the advances, there remains ambivalence towards the
dministration of contrast agents in echocardiography laboratories throughout the world, particularly in
he performance of rest studies. Therefore, this review also addresses some of the reasons for the subop-
imal uptake of contrast agents and encourages physicians, sonographers, and accreditatory bodies to
dopt adifferent approach towards thedifficult-to-imagepatient. (J AmColl Cardiol Img2010;3:188–96)
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D,uantitative assessment of left ven-
tricular (LV) volumes and left ven-
tricular ejection fraction (LVEF)
frequently mandates the timing and
ype of therapy offered to patients with cardio-
ascular disease. Therefore, physicians are in-
reasingly demanding more robust and reliable
chocardiography than ever before. However,
espite the advent of harmonic imaging, studies
re still frequently undermined by unsatisfactory
ndocardial border resolution and underestima-
ion of both LV volumes and LVEF. The main
mpediments to confident endocardial border de-
ineation are obesity, chronic lung disease, venti-
atory support, and chest wall deformities result-
ng in decreased diagnostic accuracy and poor
eproducibility (1). These shortcomings seem
articularly pronounced in patients undergoing
tress echocardiography. Near field noise, clut-
er, and reverberation also hinder the identifi-
ation of apical abnormalities with unenhanced
cans such as LV thrombus, apical hypertro-
hic cardiomyopathy, and noncompaction.
any of the misgivings concerning the accu-
rom the Department of Cardiology, Northwick Park Hospital, Ha
esearch grants from Bracco Imaging (Milan, Italy). Sanjiv Kaul, Manuscript received May 27, 2009; revised manuscript received Augusacy of echocardiography in the assessment of
V function and structure have been largely
vercome by the development of ultrasound
ontrast agents that confer a benefit over har-
onic imaging (2).
rinciples of Contrast Imaging
ontrast echocardiography essentially en-
ances discrimination between myocardial tis-
ue and the blood pool by opacifying the LV
avity and simultaneously making the myocar-
ium appear dark. Effective LV opacification is
chieved by the intravenous administration of
ngineered microbubbles that consist of a gas
ontained by an outer shell. In general, micro-
ubbles generate echo contrast by increasing
ackscatter in an ultrasound field. The nature of
ackscatter is related to the degree of micro-
ubble contraction and expansion (oscillation),
hich in turn is affected by the acoustic power of
he transmitted ultrasound field or the mechani-
al index (MI). Harmonic imaging was devel-
ped primarily as a contrast specific imaging
, United Kingdom. Professor Senior has received
served as Guest Editor for this article.t 18, 2009, accepted September 17, 2009.
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189odality that utilizes the nonlinear scattering proper-
ies of ultrasound contrast agents. However, tissue also
enerates a harmonic signal as ultrasound propagates
hrough it, and a high-quality contrast-enhanced im-
ge is one in which the distribution of contrast within
he LV cavity is clearly seen without the presence of
onfounding myocardial tissue signals. Harmonic im-
ging requires relatively high MI that very quickly
ursts contrast agents, but the ongoing bubble de-
truction and suboptimal differentiation between con-
rast and tissue, make it an unsuitable imaging mo-
ality for continuous or “real-time” contrast imaging.
herefore, contrast-specific imaging modalities are
equired to optimally enhance the contrast-to-tissue
ackscatter signal ratio and produce meaningful LV
pacification and structure definition.
Real-time imaging is necessary to assess wall thicken-
ng during LV opacification but requires more sophisti-
ated, contrast-specific imaging modalities. These tech-
ologies utilize the nonlinear oscillations of
icrobubbles, which produce low-amplitude backscatter
hat can be distinguished from tissue signals with lower
I imaging. The 2most important real-time techniques
re power pulse inversion imaging and power modula-
ion imaging. As with traditional Doppler, both tech-
iques work by transmitting multiple pulses down each
can line of the image, but transmitted pulses are either of
lternating polarity or varying amplitude. Returning sig-
als are processed as being derived from tissue, hence
uppressed if the returning scatter is perfectly out of phase
r proportionally altered in amplitude. The remaining
onlinear signals are considered to be derived from
ontrast microbubbles and are displayed. This type of
maging is preferable to high-power imaging for LV
ndocardial border enhancement as it discriminates ef-
ectively between the contrast-enhanced cavity and the
yocardium (Figs. 1A and 1B).
pproved Contrast Agents
he commercially available, Food and Drug Ad-
inistration (FDA)-approved contrast agents for
V opacification are Optison (GE Healthcare,
rinceton, New Jersey) (3) and Definity (Lantheus
edical Imaging, North Billerica, Massachusetts)
4), whereas the European Medicines Agency have
lso approved SonoVue (Bracco Diagnostics, Mi-
an, Italy). These 3 contrast agents are also referred
o as “second-generation” agents, providing success-
ul LV opacification in 90% of cases in which
aseline images are suboptimal compared with suc-
essful LV opacification in 64% to 81% of cases
sing Albunex (formerly manufactured by Mallinck- Codt Medical, Inc., St. Louis, Missouri), the first
ommercially available ultrasound contrast agent.
For LV opacification, contrast agents should be
dministered as a slow bolus followed by 10 ml of a
low saline flush. This allows for uniform opacifi-
ation of the LV cavity and minimizes attenuation
rtifact in the far field. Ideally, contrast should be
dministered as a continuous infusion, which offers
he advantage of maintaining the same flow rate
hroughout the study and achieving more uniform
V opacification as compared with bolus injections.
linical Applications of LV Opacification
oth the 2008 American Society of Echocardiog-
aphy consensus statement and the 2009 European
ssociation of Echocardiography (EAE) recom-
endations regarding contrast echocardi-
graphy provide clear indications as to
hen contrast agents should be utilized for
esting LV opacification (5,6). In difficult-
o-image patients requiring rest echocar-
iography with reduced image quality,
ontrast enhancement is recommended
here 2 contiguous segments are not
een on noncontrast images as well as in
atients requiring accurate assessment of
VEF regardless of image quality, with
he intention of increasing the confidence
f the interpreting physician in assessing
V volumes and systolic function. Con-
rast enhancement is also recommended in
atients requiring confirmation or exclu-
ion of LV structural abnormalities, intra-
ardiac masses, for patients in the inten-
ive care unit, and to enhance Doppler
ignals.
V endocardial delineation and assessment of LV func-
ion. The superiority of second-generation agents
n delineating the endocardium compared with
rst-generation agents has been demonstrated
3,4), and segment visualization by echo has also
een shown to be comparable to cardiac magnetic
esonance (CMR) after the administration of a
ontrast agent (7). A natural corollary to the en-
anced endocardial delineation conferred by using
ontrast agents is the ability to quantify LV volumes
nd ejection fraction more accurately (1,7–12).
nenhanced 2-dimensional echocardiography
2DE) is known to markedly underestimate LV
olumes by as much as 30% to 40% and LVEF
y 3% to 6% (7–9,13,14) when compared with
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190nenhanced 2DE is attributed not only to the poor
racking of the endocardial border with this tech-
ique, but also to the adoption of off-axis imaging
lanes and foreshortening of the LV apex. A recent
tudy of 50 patients after acute myocardial infarc-
ion demonstrated that the improvement in accu-
acy of estimation of LV volume and LVEF with
ontrast-enhanced 2DE is similar to that obtained
y unenhanced 3-dimensional echocardiography
3DE) when compared with CMR (13). In this
tudy, contrast-enhanced 3DE was superior to both
echniques and provided LV volumes and LVEF
ata approximating those obtained with CMR. The
fficacy of contrast agents in enhancing quantifica-
Achieving Satisfactory LV Opaciﬁcation With Real-Time Imaging
ted left ventricular (LV) opaciﬁcation with high mechanical index
sults in contrast destruction particularly at the apex and a poorly
docardial border. (B) LV opaciﬁcation with low mechanical index
lows better discrimination between the LV cavity and the myocar-
itating wall motion assessment.ion of LVEF is also reviewed in detail in both the american Society of Echocardiography (5) and
AE (6) consensus documents concerning contrast
chocardiography.
ssessment of cardiac structure with LV opaciﬁcation.
s mentioned previously, satisfactory imaging of
he LV apex is often confounded by near-field
rtifacts. LV thrombus, usually located in the LV
pex, often has to be excluded in patients with low
VEF (Fig. 2), apical aneurysms, or thromboem-
olic phenomena. In a retrospective study of 409
atients who underwent unenhanced tissue harmonic
maging, 46% of scans were deemed nondiagnostic for
his purpose. After an additional study with contrast
dministration, 90% of these scans provided definitive
iagnostic information for establishing or excluding the
resence of thrombus (15).
Contrast echocardiography is also recognized as the
echnique of choice in the investigation of patients
ith suspected apical hypertrophic cardiomyopathy
16) (Fig. 3), LV noncompaction (17) (Fig. 4), myo-
ardial rupture, and LV pseudoaneurysm (18).
linical Efficacy of Contrast-Enhanced
tress Echocardiography
onventional stress echocardiography is well estab-
ished, with a high sensitivity and specificity for the
iagnosis of coronary artery disease (CAD). How-
ver, endocardial visualization can be compromised
uring stress echocardiography by chest wall move-
ent during hyperventilation (with exercise stress)
nd cardiac translational movement during tachy-
ardia. Poor quality studies have been shown to be
ess reproducible and to have low interobserver
greement (19). Moreover, quick and reliable ac-
uisition of diagnostic quality images is mandated
uring stress echocardiography, particularly when
xercise stress is undertaken.
The benefit of ultrasonic contrast agents in en-
ocardial delineation during stress studies has been
onfirmed unequivocally. Second-generation con-
rast agents have shown improved endocardial res-
lution, greater concordance in test interpretation,
nd greater confidence in wall motion analysis even
y less experienced readers (20–22).
The improved image quality and endocardial
order definition during contrast-enhanced stress
chocardiography has translated into improved sen-
itivity and accuracy of the technique for the detec-
ion of CAD (23–26). The routine use of LV
pacification, regardless of baseline image quality,
n improving the accuracy of diagnosing CAD hasFigure 1.
(A) Attemp
imaging re
deﬁned en
imaging allso been confirmed (27).
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191an Rest Contrast Imaging Have a
Clinical Impact”?
here have been 2 studies to date that have ad-
ressed the clinical impact of contrast echocardiog-
aphy when assessing LV function. One study
emonstrated that contrast echocardiography
hould be routinely used after acute myocardial
nfarction for better prediction of hard cardiac
nd points compared with unenhanced echocar-
iography (Fig. 5) (28). Until recently, there had
lso been little evidence for rest contrast echocar-
iography in conferring a clinical impact upon a
atient’s subsequent management, such as alter-
tions in their therapy or avoidance of down-
tream tests (Fig. 6). A study by Kurt et al. (29)
ought to ascertain the day-to-day impact of
ontrast echocardiography upon the clinical care
f 632 consecutive patients who had undergone
oth unenhanced and contrast-enhanced echocar-
iograms as part of their routine care. Patients with
chocardiography deemed technically difficult had
heir scans repeated with an appended contrast-
nhanced examination, with both sets of images in-
erpreted by independent observers. The primary phy-
ician of the patient was then contacted with the
esults of the unenhanced scan, and the impact it
ould have on the patient’s subsequent management
as recorded. The results of the contrast-enhanced
chocardiogram were then revealed to the primary
hysician, and any alterations to the patient’s manage-
ent, if any, were documented. Impact upon cardio-
ascular management referred to initiation or discon-
inuation of medications (inotropes, diuretics,
ntravenous fluids, vasodilators, anticoagulants) and
he need for further diagnostic studies (transesopha-
eal echocardiography, radionuclide imaging, stress
esting, coronary angiography). After contrast LV
pacification, the proportion of uninterpretable stud-
es decreased from 11.7% to 0.3% and of technically
ifficult studies decreased from 86.7% to 9.8%. This
ed to a significant avoidance of further diagnostic
rocedures in patients, primarily due to improved
ssessment of LV function. Of the patients who
ltimately underwent further testing, 67% of these
ere based on the findings of the contrast echocar-
iogram. Medical therapy was altered in11% of the
atients in this study after interpretation of the con-
rast study, and combined with the avoidance of
urther downstream tests, a total of 35.6% patients
eceiving contrast experienced a significant impact on
heir clinical care. sost Efficiency of Contrast Agents
he improved image quality afforded by LV opacifi-
ation not only improves clinical efficacy, but can also
esult in a more cost-effective paradigm of care. The
ost obvious method of cost saving is through the
eduction of downstream, additional tests that are
ncurred as a result of an initially nondiagnostic
chocardiographic study. Administration of contrast
gents reduces potential downstream testing by
33%, with an average cost saving of $122 per patient
29). Improved image quality can also realize cost
avings through enhanced diagnostic accuracy and
educing the false positive and false negative rate,
lthough the magnitude of this effect is more difficult
o quantify.
The improved diagnostic yield achieved with
ontrast-enhanced stress echocardiography has been
hown to result in only 12% of patients requiring
urther downstream testing, compared with 42% of
atients who received unenhanced stress scans (30).
hanigaraj et al. (31) defined the cost effectiveness of
ontrast usage in patients with suboptimal image
uality during stress echocardiography. During a
-week period following stress echocardiography, 53%
f patients who underwent suboptimal, unenhanced
cans required additional testing in the form of nuclear
cintigraphy. Administration of contrast in a group with
Figure 2. Apical Thrombus
A mobile, large thrombus is clearly visualized on administration of
sound contrast agent in this patient who suffered an acute myocar
infarction in the left anterior descending artery.ultra-
dialimilar quality scans resulted in a saving of $238 per
noncompaction.
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192Figure 3. Apical Hypertrophic Cardiomyopathy
(A) An unenhanced, 3-chamber echocardiogram at rest in a
70-year-old woman referred for stress echocardiography to
investigate breathlessness is of poor quality but does not sug-
gest any signiﬁcant structural disease. Following administration
of a contrast agent, the characteristic spade-like left ventricular
cavity contour is fully appreciated in both (B) diastole and (C)
end-systole, permitting the diagnosis of apical hypertrophic car-
diomyopathy to be made.Figure 4. LV Noncompaction
(A) The resting, unenhanced scan in a patient referred for stress
echocardiography to investigate chest pain is of poor quality
and nondiagnostic. After left ventricular (LV) opaciﬁcation, multi-
ple deep trabeculations (arrows) of the LV myocardium are seen
in (B) the lateral (4-chamber view) and (C) the posterior
(3-chamber view) walls involving the apex, typical of LV
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193atient. Contrast-enhanced stress echocardiography has
lso been proven to be cost effective in the acute setting.
n a United Kingdom study, stress echocardiography
ith contrast was performed in 15%of patients, and even
hen extrapolated to 30% of cases, resulted in reduced
ownstream costs compared with exercise ECG for the
etection of CAD in patients presenting with troponin-
egative acute chest pain (32).
he Ambivalence Towards Contrast Agents
espite the clinical evidence supporting LV opaci-
cation in terms of clinical efficacy and cost effi-
iency, there clearly remains a considerable ambi-
alence towards using ultrasound contrast agents
espite reimbursement being widely available. As
entioned previously, 11% of unenhanced scans
re deemed uninterpretable in a real-world setting
ith respect to making a reliable assessment of LV
unction (29). However, during 2008, a total of
22,236,000 transthoracic rest scans were per-
ormed in the U.S., of which 93,000 (0.4%) were
erformed with either Definity or Optison admin-
stration for the purpose of LV opacification (33).
hese figures starkly convey the large proportion of
chocardiograms that are being performed and
nterpreted that do not even provide the most basic
nd important data one would expect from them.
Efforts are required by individuals, departments,
nd organizations alike to remove impediments per-
eived to be restricting the uptake of contrast ultra-
ound agents in the performance of rest echocardio-
rams. The role of physician leaders in ensuring that
ood quality scans are being performed in their echo-
ardiography laboratory cannot be underestimated (5).
s well as providing training and assistance in the
echnical aspects of successfully administering con-
rast, the physician must remove the complacency,
hich has crept into echocardiography, of accepting
oor quality images. This complacency is probably the
iggest barrier confronting advocates of contrast echo-
ardiography, and it is here that organizations and
ccreditatory bodies could have an impact. At present,
either the Intersocietal Commission for the Accred-
tation of Echocardiography Laboratories (ICAEL)
or the EAE Laboratory Accreditation module sug-
est, let alone mandate, the use of contrast agents
hen baseline imaging is poor. Both the British
ociety of Echocardiography and the EAE require
ubmission of a logbook of 250 studies representa-
ive of typical pathologies encountered in the echo
aboratory to achieve individual transthoracic echo-
ardiography accreditation. However, none of these acans are required to demonstrate examples of the
iagnostic benefit that can be achieved with contrast
nhancement. Echo laboratories seeking national/
nternational accreditation in transthoracic echocardi-
graphy should be required to provide the necessary
acilities, training, and expertise to perform contrast
chocardiography in patients who meet the criteria as
efined by societal guidelines. After appropriate train-
ng in intravenous cannulation and contrast agent
dministration, a member of the laboratory personnel,
ither a sonographer or nurse, should be identified as
eing capable of performing a contrast-enhanced scan
here necessary. A move towards setting obligatory
olicies by accreditation agencies for contrast use
hen image quality is poor together with a mandate
hat sonographers applying for individual accredita-
ion perform at an agreed number of contrast-
nhanced scans will help to empower the sonographer
o change his/her approach towards the difficult-to-
can patient. There are also concerns that contrast
tudies are time consuming; however, “sonographer-
riven” contrast echocardiography has been shown to
educe the total time required to perform a contrast-
nhanced study to less than the time required to
erform an unenhanced, technically difficult study
34). An accredited echo laboratory should have a
esignated sonographer or nurse who has been appro-
riately trained to perform intravenous cannulation
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194ependency of the laboratory on the availability of a
hysician to perform the test. If the contrast-
nhancement is not felt to be feasible at the time of
he initial study, the patient could be invited back to a
edicated LV opacification out-patient clinic, al-
hough this would be a less desirable arrangement.
The reluctance to perform contrast studies may also
e due to residual fears, or misperceptions, regarding
he safety profile of contrast agents. The concerns
egarding ultrasound contrast agents arose primarily
Avoidance of Further Downstream Tests After
cation
enhanced, 4-chamber image taken at end-systole was reported as
xtensive wall motion abnormalities (arrows) in a patient being
d for atypical chest pain who was duly referred for coronary
y. (B) The echocardiogram was repeated with left ventricular (LV)
n, clearly demonstrating normal wall thickening during systole,
he need for invasive coronary angiography as a ﬁrst-line investi-
his patient’s symptoms.ated at 1 death per 500,000 contrast injections in the
.S.) that occurred in temporal relation to contrast
dministration in patients with significant underlying,
nstable cardiovascular disease. However, it is worth
eiterating that after a temporary withdrawal of the
pproval for Sonovue for use in cardiac applications by
he European Medicines Agency in 2004, the com-
ittee soon restored its approval for patients not
uffering suspected acute coronary syndrome or unsta-
le heart disease. Likewise, the black-box warning
ssued by the FDA for Definity in 2007 was reviewed,
nd initially, several new contraindications were im-
osed on its use (acute myocardial infarction, unstable
eart failure, unstable arrhythmias, respiratory failure,
echanical ventilation, pulmonary emboli), which
ere felt to be unnecessary and expose critically unwell
atients to alternative, more invasive diagnostic pro-
edures. Moreover, the potential effect of pseudocom-
lication confounding the interpretation of safety was
aised and later confirmed by large, retrospective
nalyses that found no difference in complication rate
o a matched cohort undergoing unenhanced studies
35,36). The FDA reviewed the new restrictions in
ay and June 2008, and subsequently lifted the new
ontraindications, replacing them with warnings
nstead.
onclusions
ontrast echocardiography has been shown to be
linically effective, to reduce down stream costs and
o spare the patient further, potentially hazardous
nvestigations. The enhanced diagnostic accuracy
onferred by ultrasound contrast agents should
ake them indispensible in routine as well as in the
ore advanced echocardiographic examinations,
ut contrast uptake remains woefully poor. To fully
ealize the potential of contrast echocardiography,
e must remove both the complacency surrounding
he acquisition of suboptimal rest studies and the
freedom” of echo laboratories to avoid LV opaci-
cation if they choose through the implementation
f mandatory policies for the application of contrast
gents by existing accreditatory bodies.
eprint requests and correspondence: Prof. Roxy Senior,
epartment of Cardiovascular Medicine, Northwick
ark Hospital, Harrow HA1 3UJ, United Kingdom.after a handful of deaths over a 6-year period (esti- E-mail: roxysenior@cardiac-research.org.Figure 6.
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